Audentes Therapeutics, Inc.

Audentes Therapeutics, Inc., incorporated on November 13, 2012, is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.The Company competes with Genethon, Promethera, Alexion, Moderna, Genzyme Corporation, Amicus Therapeutics, Inc., Valerion Therapeutics, LLC and Oxyrane UK Limited.

Bank Name Audentes Therapeutics, Inc.
Stock Exchange NASDAQ
Symbol BOLD
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region America
Chairman
CEO Mr. Matthew R. Patterson
Employees 152
Website www.audentestx.com
Registered Year 2012

UpdateContent
UpdateContent
UpdateContent